Bank of America Securities Remains a Buy on Teva Pharmaceutical (TEVA)

Tip Ranks
2025.12.09 10:35

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Teva Pharmaceutical with a $32.00 price target. Teva's shares closed at $28.33, and the analyst consensus is Strong Buy with a $31.22 price target. Barclays also initiated coverage with a Buy rating and a $35.00 price target.

In a report released yesterday, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical, with a price target of $32.00. The company’s shares closed yesterday at $28.33.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and Jazz Pharmaceuticals. According to TipRanks, Gerberry has an average return of 15.0% and a 60.49% success rate on recommended stocks.

Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $31.22, which is a 10.20% upside from current levels. In a report released yesterday, Barclays also initiated coverage with a Buy rating on the stock with a $35.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.